Literature DB >> 25055256

Molecular targeted α-particle therapy for oncologic applications.

Thaddeus J Wadas1, Darpan N Pandya, Kiran Kumar Solingapuram Sai, Akiva Mintz.   

Abstract

OBJECTIVE: A significant challenge facing traditional cancer therapies is their propensity to significantly harm normal tissue. The recent clinical success of targeting therapies by attaching them to antibodies that are specific to tumor-restricted biomarkers marks a new era of cancer treatments.
CONCLUSION: In this article, we highlight the recent developments in α-particle therapy that have enabled investigators to exploit this highly potent form of therapy by targeting tumor-restricted molecular biomarkers.

Entities:  

Keywords:  213Bi; 223Ra; 225Ac; molecular radiotherapy; nuclear medicine; radioimmunotherapy; α-particle therapy

Mesh：

Substances：

Year:  2014        PMID： 25055256      PMCID： PMC4490786          DOI： 10.2214/AJR.14.12554

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN： 0361-803X            Impact factor:   3.959


  85 in total

1.  Radioimmunotherapy in non-Hodgkin lymphoma: opinions of U.S. medical oncologists and hematologists.

Authors:  Niklaus G Schaefer; Jiemin Ma; Peng Huang; Judy Buchanan; Richard L Wahl
Journal:  J Nucl Med       Date:  2010-05-19       Impact factor: 10.057

Review 2.  Radioimmunotherapy with alpha-emitting nuclides.

Authors:  M R McDevitt; G Sgouros; R D Finn; J L Humm; J G Jurcic; S M Larson; D A Scheinberg
Journal:  Eur J Nucl Med       Date:  1998-09

Review 3.  Tumour targeting with radiometals for diagnosis and therapy.

Authors:  Caterina F Ramogida; Chris Orvig
Journal:  Chem Commun (Camb)       Date:  2013-05-25       Impact factor: 6.222

4.  Human Cerenkov imaging using 18F-FDG.

Authors:  Antonello E Spinelli; Federico Boschi
Journal:  J Nucl Med       Date:  2014-01-21       Impact factor: 10.057

5.  Trastuzumab emtansine for HER2-positive advanced breast cancer.

Authors:  Sunil Verma; David Miles; Luca Gianni; Ian E Krop; Manfred Welslau; José Baselga; Mark Pegram; Do-Youn Oh; Véronique Diéras; Ellie Guardino; Liang Fang; Michael W Lu; Steven Olsen; Kim Blackwell
Journal:  N Engl J Med       Date:  2012-10-01       Impact factor: 91.245

6.  Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance p.

Authors:  Stefan Kneifel; Dominik Cordier; Stephan Good; Mihai C S Ionescu; Anthony Ghaffari; Silvia Hofer; Martin Kretzschmar; Markus Tolnay; Christos Apostolidis; Beatrice Waser; Marlene Arnold; Jan Mueller-Brand; Helmut R Maecke; Jean Claude Reubi; Adrian Merlo
Journal:  Clin Cancer Res       Date:  2006-06-15       Impact factor: 12.531

7.  Tc-labeling of Peptidomimetic Antagonist to Selectively Target alpha(v)beta(3) Receptor-Positive Tumor: Comparison of PDA and EDDA as co-Ligands.

Authors:  In Soo Shin; Jin Soo Maeng; Beom-Su Jang; Eric You; Kenneth Cheng; King C P Li; Bradford Wood; Jorge A Carrasquillo; S Narasimhan Danthi; Chang H Paik
Journal:  Curr Radiopharm       Date:  2010-01-01

8.  Bismuth-213 radioimmunotherapy with C595 anti-MUC1 monoclonal antibody in an ovarian cancer ascites model.

Authors:  Emma Y Song; Chang F Qu; Syed M A Rizvi; Chand Raja; Julia Beretov; Alfred Morgenstern; Christos Apostolidis; Frank Bruchertseifer; Alan Perkins; Barry J Allen
Journal:  Cancer Biol Ther       Date:  2007-10-08       Impact factor: 4.742

9.  Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates.

Authors:  Matthias Miederer; Michael R McDevitt; George Sgouros; Kim Kramer; Nai-Kong V Cheung; David A Scheinberg
Journal:  J Nucl Med       Date:  2004-01       Impact factor: 10.057

10.  Quantitative modeling of Cerenkov light production efficiency from medical radionuclides.

Authors:  Bradley J Beattie; Daniel L J Thorek; Charles R Schmidtlein; Keith S Pentlow; John L Humm; Andreas H Hielscher
Journal:  PLoS One       Date:  2012-02-20       Impact factor: 3.240
View more
  18 in total

1.  (99m)Tc-bioorthogonal click chemistry reagent for in vivo pretargeted imaging.

Authors:  María Fernanda García; Xiuli Zhang; Manankumar Shah; Jessica Newton-Northup; Pablo Cabral; Hugo Cerecetto; Thomas Quinn
Journal:  Bioorg Med Chem       Date:  2016-01-29       Impact factor: 3.641

2.  Alpha Particle Enhanced Blood Brain/Tumor Barrier Permeabilization in Glioblastomas Using Integrin Alpha-v Beta-3-Targeted Liposomes.

Authors:  Anirudh Sattiraju; Xiaobing Xiong; Darpan N Pandya; Thaddeus J Wadas; Ang Xuan; Yao Sun; Youngkyoo Jung; Kiran Kumar Solingapuram Sai; Jay F Dorsey; King C Li; Akiva Mintz
Journal:  Mol Cancer Ther       Date:  2017-06-15       Impact factor: 6.261

3.  Automated cassette-based production of high specific activity [203/212Pb]peptide-based theranostic radiopharmaceuticals for image-guided radionuclide therapy for cancer.

Authors:  Mengshi Li; Xiuli Zhang; Thomas P Quinn; Dongyoul Lee; Dijie Liu; Falk Kunkel; Brian E Zimmerman; Daniel McAlister; Keith Olewein; Yusuf Menda; Saed Mirzadeh; Roy Copping; Frances L Johnson; Michael K Schultz
Journal:  Appl Radiat Isot       Date:  2017-05-10       Impact factor: 1.513

Review 4.  Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups.

Authors:  David Taïeb; Abhishek Jha; Giorgio Treglia; Karel Pacak
Journal:  Endocr Relat Cancer       Date:  2019-11       Impact factor: 5.678

5.  Modeling Cell and Tumor-Metastasis Dosimetry with the Particle and Heavy Ion Transport Code System (PHITS) Software for Targeted Alpha-Particle Radionuclide Therapy.

Authors:  Dongyoul Lee; Mengshi Li; Bryan Bednarz; Michael K Schultz
Journal:  Radiat Res       Date:  2018-06-26       Impact factor: 2.841

6.  Targeted α-Therapy in Cancer Management: Synopsis of Preclinical and Clinical Studies.

Authors:  Hossein Jadvar
Journal:  Cancer Biother Radiopharm       Date:  2020-03-23       Impact factor: 3.099

7.  Effect of microdistribution of alpha and beta-emitters in targeted radionuclide therapies on delivered absorbed dose in a GATE model of bone marrow.

Authors:  Jonathan Tranel; Felix Y Feng; Sara St James; Thomas A Hope
Journal:  Phys Med Biol       Date:  2021-01-29       Impact factor: 3.609

8.  Automated astatination of biomolecules--a stepping stone towards multicenter clinical trials.

Authors:  Emma Aneheim; Per Albertsson; Tom Bäck; Holger Jensen; Stig Palm; Sture Lindegren
Journal:  Sci Rep       Date:  2015-07-14       Impact factor: 4.379

Review 9.  Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle.

Authors:  Yana Dekempeneer; Marleen Keyaerts; Ahmet Krasniqi; Janik Puttemans; Serge Muyldermans; Tony Lahoutte; Matthias D'huyvetter; Nick Devoogdt
Journal:  Expert Opin Biol Ther       Date:  2016-05-19       Impact factor: 4.388

10.  Preliminary Therapy Evaluation of (225)Ac-DOTA-c(RGDyK) Demonstrates that Cerenkov Radiation Derived from (225)Ac Daughter Decay Can Be Detected by Optical Imaging for In Vivo Tumor Visualization.

Authors:  Darpan N Pandya; Roy Hantgan; Mikalai M Budzevich; Nancy D Kock; David L Morse; Izadora Batista; Akiva Mintz; King C Li; Thaddeus J Wadas
Journal:  Theranostics       Date:  2016-03-01       Impact factor: 11.556
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.